{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:59:52Z","timestamp":1790269192170,"version":"4.1.0"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA279834"],"award-info":[{"award-number":["R37CA279834"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R37CA279822-01"],"award-info":[{"award-number":["1R37CA279822-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010900","name":"Yale Cancer Center","doi-asserted-by":"publisher","award":["P30CA016359"],"award-info":[{"award-number":["P30CA016359"]}],"id":[{"id":"10.13039\/100010900","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoiotech.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immuno-Oncology and Technology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.iotech.2026.101611","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:55:23Z","timestamp":1788825323000},"page":"101611","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Reviving cancer vaccines in renal cell carcinoma: a new chapter in immunotherapy for kidney cancer"],"prefix":"10.1016","volume":"31","author":[{"given":"F.M.","family":"Scallo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4543-5553","authenticated-orcid":false,"given":"D.A.","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.iotech.2026.101611_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA. Cancer J Clin"},{"key":"10.1016\/j.iotech.2026.101611_bib2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.eururo.2025.06.005","article-title":"Epidemiology of renal cancer: incidence, mortality, survival, genetic predisposition, and risk factors","volume":"88","author":"Larcher","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.iotech.2026.101611_bib3","series-title":"EAU Guidelines","year":"2024"},{"key":"10.1016\/j.iotech.2026.101611_bib4","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41585-019-0211-5","article-title":"The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications","volume":"16","author":"Linehan","year":"2019","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.iotech.2026.101611_bib5","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.iotech.2026.101611_bib6","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1200\/JCO.2003.02.122","article-title":"Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer","volume":"21","author":"Yang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.iotech.2026.101611_bib7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1470-2045(19)30735-1","article-title":"Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study","volume":"21","author":"Rini","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.iotech.2026.101611_bib8","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.iotech.2026.101611_bib9","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.iotech.2026.101611_bib10","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.iotech.2026.101611_bib11","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.iotech.2026.101611_bib12","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00345-016-1773-y","article-title":"Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study","volume":"34","author":"Dabestani","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.iotech.2026.101611_bib13","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal heterogeneity and tumor evolution: past, present, and the future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.iotech.2026.101611_bib14","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1016\/j.cell.2022.06.035","article-title":"Cancer vaccines: building a bridge over troubled waters","volume":"185","author":"Sellars","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.iotech.2026.101611_bib15","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.iotech.2026.101611_bib16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.iotech.2026.101611_bib17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3233\/KCA-230006","article-title":"Antigenic targets in clear cell renal cell carcinoma","volume":"7","author":"Schindler","year":"2023","journal-title":"Kidney Cancer"},{"key":"10.1016\/j.iotech.2026.101611_bib18","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/vaccines3020344","article-title":"Whole tumor antigen vaccines: where are we?","volume":"3","author":"Chiang","year":"2015","journal-title":"Vaccines"},{"key":"10.1016\/j.iotech.2026.101611_bib19","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41416-023-02327-6","article-title":"Whole tumour cell-based vaccines: tuning the instruments to orchestrate an optimal antitumour immune response","volume":"129","author":"P\u00e9rez-Ba\u00f1os","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.iotech.2026.101611_bib20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.smim.2010.02.004","article-title":"Whole tumor antigen vaccines","volume":"22","author":"Chiang","year":"2010","journal-title":"Semin Immunol"},{"key":"10.1016\/j.iotech.2026.101611_bib21","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1002\/(SICI)1097-0142(19960615)77:12<2560::AID-CNCR20>3.0.CO;2-P","article-title":"Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and Bacillus Calmette-Gu\u00e8rin: five-year results of a prospective randomized study","volume":"77","author":"Galligioni","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.iotech.2026.101611_bib22","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0140-6736(04)15590-6","article-title":"Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial","volume":"363","author":"Jocham","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.iotech.2026.101611_bib23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(08)60697-2","article-title":"An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial","volume":"372","author":"Wood","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.iotech.2026.101611_bib24","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1158\/1078-0432.CCR-19-2427","article-title":"Results of the ADAPT phase 3 study of rocapuldencel-T in combination with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma","volume":"26","author":"Figlin","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.iotech.2026.101611_bib25","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/1097-0142(19810415)47:8<1984::AID-CNCR2820470814>3.0.CO;2-J","article-title":"Specific immunotherapy of advanced renal carcinoma: evidence for the polyclonality of metastases","volume":"47","author":"McCune","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.iotech.2026.101611_bib26","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/BF01741726","article-title":"Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells","volume":"32","author":"McCune","year":"1990","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.iotech.2026.101611_bib27","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/1097-0142(19800901)46:5<1128::AID-CNCR2820460509>3.0.CO;2-3","article-title":"Active specific immunotherapy of stage IV renal carcinoma with aggregated tumor antigen adjuvant","volume":"46","author":"Neidhart","year":"1980","journal-title":"Cancer"},{"key":"10.1016\/j.iotech.2026.101611_bib28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0022-5347(01)66661-8","article-title":"Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma","volume":"155","author":"Gastl","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.iotech.2026.101611_bib29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF00942091","article-title":"Molecular regulation of intercellular adhesion molecule 1 (ICAM-1) expression in renal cell carcinoma","volume":"25","author":"Tanabe","year":"1997","journal-title":"Urol Res"},{"key":"10.1016\/j.iotech.2026.101611_bib30","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1053\/j.seminoncol.2006.06.011","article-title":"Vaccines in renal cell carcinoma","volume":"33","author":"Kubler","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1016\/j.iotech.2026.101611_bib31","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(04)16169-2","article-title":"Renal-cell carcinoma: vaccination and risk of tumour progression","volume":"363","author":"Kommu","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.iotech.2026.101611_bib32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/77835","article-title":"CD91: a receptor for heat shock protein gp96","volume":"1","author":"Binder","year":"2000","journal-title":"Nat. Immunol"},{"key":"10.1016\/j.iotech.2026.101611_bib33","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.2007.11.9941","article-title":"Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician\u2019s choice of treatment for stage IV melanoma: the C-100-21 study group","volume":"26","author":"Testori","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.iotech.2026.101611_bib34","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-08-1332","article-title":"Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients","volume":"15","author":"Ko","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.iotech.2026.101611_bib35","doi-asserted-by":"crossref","first-page":"6674","DOI":"10.1158\/1078-0432.CCR-07-5212","article-title":"Sunitinib reversestype-1 immune suppression and decreases t-regulatory cells in renal cell carcinoma patients","volume":"14","author":"Finke","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.iotech.2026.101611_bib36","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40425-015-0055-3","article-title":"Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): phase 2 study results","volume":"3","author":"Amin","year":"2015","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.iotech.2026.101611_bib37","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/1744-9987.12694","article-title":"Vaccination of urological cancer patients with WT1 peptide-pulsed dendritic cells in combination with molecular targeted therapy or conventional chemotherapy induces immunological and clinical responses","volume":"22","author":"Ogasawara","year":"2018","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.iotech.2026.101611_bib38","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/CJI.0b013e3181833818","article-title":"Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1\/2 trial","volume":"31","author":"Berntsen","year":"2008","journal-title":"J Immunother"},{"key":"10.1016\/j.iotech.2026.101611_bib39","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/bjc.2013.90","article-title":"Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma","volume":"108","author":"Yoshimura","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.iotech.2026.101611_bib40","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00262-010-0935-9","article-title":"A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings","volume":"60","author":"Oudard","year":"2011","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1016\/j.iotech.2026.101611_bib41","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1158\/1078-0432.CCR-05-2253","article-title":"A phase I trial of vaccination of CA9-derived peptides for hla-a24-positive patients with cytokine-refractory metastatic renal Cell carcinoma","volume":"12","author":"Uemura","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.iotech.2026.101611_bib42","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-10-2082","article-title":"Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study","volume":"16","author":"Amato","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.iotech.2026.101611_bib43","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/modpathol.3800588","article-title":"Immunohistochemical detection of WT1 protein in a variety of cancer cells","volume":"19","author":"Nakatsuka","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.iotech.2026.101611_bib44","doi-asserted-by":"crossref","first-page":"13885","DOI":"10.1073\/pnas.0405884101","article-title":"Induction of WT1 (Wilms\u2019 tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression","volume":"101","author":"Oka","year":"2004","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.iotech.2026.101611_bib45","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bjh.12637","article-title":"Wilms\u2019 tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses","volume":"164","author":"Uttenthal","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.iotech.2026.101611_bib46","first-page":"5495","article-title":"Wilms\u2019 tumor gene 1 (WT1)\u2014loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I\/II clinical trial","volume":"33","author":"Coosemans","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.iotech.2026.101611_bib47","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3390\/biomedicines10040912","article-title":"Evaluating established roles, future perspectives and methodological heterogeneity for Wilms\u2019 tumor 1 (WT1) antigen detection in adult renal cell carcinoma, using a novel n-terminus targeted antibody (clone WT49)","volume":"10","author":"Novacescu","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.iotech.2026.101611_bib48","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/j.1349-7006.2008.00870.x","article-title":"Cancer cells survive with survivin","volume":"99","author":"Yamamoto","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1016\/j.iotech.2026.101611_bib49","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s00262-009-0691-x","article-title":"Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer","volume":"58","author":"Honma","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.iotech.2026.101611_bib50","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1479-5876-2-19","article-title":"Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer","volume":"2","author":"Tsuruma","year":"2004","journal-title":"J Transl Med"},{"key":"10.1016\/j.iotech.2026.101611_bib51","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00262-016-1890-x","article-title":"Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma","volume":"65","author":"Fenstermaker","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.iotech.2026.101611_bib52","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s13046-021-02026-1","article-title":"Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1\u03b1, HIF2\u03b1, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma","volume":"40","author":"Li","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.iotech.2026.101611_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104032","article-title":"Application of VEGF\/VEGFR peptide vaccines in cancer: a systematic review of clinical trials","volume":"187","author":"Zahedipour","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.iotech.2026.101611_bib54","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1309\/1F99-BPDY-7DHH-9G97","article-title":"MUC1 expression is correlated with nuclear grade and tumor progression in pT1 renal clear cell carcinoma","volume":"118","author":"Leroy","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.iotech.2026.101611_bib55","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/modpathol.3800032","article-title":"Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases","volume":"17","author":"Langner","year":"2004","journal-title":"Mod Pathol"},{"key":"10.1016\/j.iotech.2026.101611_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110888","article-title":"A review on development of MUC1-based cancer vaccine","volume":"132","author":"Gao","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.iotech.2026.101611_bib57","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1309\/AJCPPPR57HNJMSLZ","article-title":"Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade","volume":"134","author":"Genega","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.iotech.2026.101611_bib58","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/CJI.0000000000000336","article-title":"A phase I, open-label, dose-escalation, and cohort expansion study to evaluate the safety and immune response to autologous dendritic cells transduced with AdGMCA9 (DC-AdGMCAIX) in patients with metastatic renal cell carcinoma","volume":"43","author":"Faiena","year":"2020","journal-title":"J Immunother"},{"key":"10.1016\/j.iotech.2026.101611_bib59","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1158\/1078-0432.CCR-08-0668","article-title":"Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial","volume":"14","author":"Amato","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.iotech.2026.101611_bib60","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/CJI.0b013e3181ace876","article-title":"Vaccination of renal cell cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-a (IFN-a)","volume":"32","author":"Amato","year":"2009","journal-title":"J Immunother"},{"key":"10.1016\/j.iotech.2026.101611_bib61","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1479-5876-7-2","article-title":"Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma","volume":"7","author":"Kaufman","year":"2009","journal-title":"J Transl Med"},{"key":"10.1016\/j.iotech.2026.101611_bib62","first-page":"424","article-title":"Vaccination of patients with metastatic renal cancer with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-\u03b1","volume":"32","author":"Hawkins","year":"2009","journal-title":"J Immunother Off J Soc Biol Ther"},{"key":"10.1016\/j.iotech.2026.101611_bib63","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/sj.bjc.6602776","article-title":"Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy","volume":"93","author":"Griffiths","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.iotech.2026.101611_bib64","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/PAI.0000000000001101","article-title":"Immunohistochemical detection of 5T4 in renal cell carcinoma","volume":"31","author":"Miller","year":"2023","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"8","key":"10.1016\/j.iotech.2026.101611_bib65","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/nm.2883","article-title":"Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival","volume":"18","author":"Walter","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.iotech.2026.101611_bib66","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/S1470-2045(16)30408-9","article-title":"IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"17","author":"Rini","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.iotech.2026.101611_bib67","first-page":"1695","article-title":"Combination of Sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy","volume":"136","author":"Jaini","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.iotech.2026.101611_bib68","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3389\/fimmu.2019.00467","article-title":"Therapeutic cancer vaccine and combinations with antiangiogenic therapies and immune checkpoint blockade","volume":"10","author":"Terme","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.iotech.2026.101611_bib69","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1158\/2326-6066.CIR-13-0022","article-title":"Getting personal with neoantigen-based therapeutic cancer vaccines","volume":"1","author":"Hacohen","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.iotech.2026.101611_bib70","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.iotech.2026.101611_bib71","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.iotech.2026.101611_bib72","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.iotech.2026.101611_bib73","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","article-title":"A neoantigen vaccine generates antitumour immunity in renal cell carcinoma","volume":"639","author":"Braun","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.iotech.2026.101611_bib74","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1479-5876-8-8","article-title":"A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma","volume":"8","author":"Rahma","year":"2010","journal-title":"J Transl Med"},{"key":"10.1016\/j.iotech.2026.101611_bib75","doi-asserted-by":"crossref","first-page":"7582","DOI":"10.1158\/1078-0432.CCR-09-2131","article-title":"Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma","volume":"15","author":"Young","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.iotech.2026.101611_bib76","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.iotech.2026.101611_bib77","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.iotech.2026.101611_bib78","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.iotech.2026.101611_bib79","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s43018-024-00896-w","article-title":"Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma","volume":"6","author":"Jammihal","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.iotech.2026.101611_bib80","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.1038\/s41467-020-19464-8","article-title":"Human endogenous retroviruses form a reservoir of T cell targets in hematological cancers","volume":"11","author":"Saini","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.iotech.2026.101611_bib81","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1172\/JCI34409C1","article-title":"Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells","volume":"118","author":"Takahashi","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.iotech.2026.101611_bib82","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.cell.2025.01.046","article-title":"HIF regulates multiple translated endogenous retroviruses: implications for cancer immunotherapy","volume":"188","author":"Jiang","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.iotech.2026.101611_bib83","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.1172\/JCI121476","article-title":"Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma","volume":"128","author":"Smith","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.iotech.2026.101611_bib84","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1158\/1078-0432.CCR-21-3501","article-title":"The challenges of HLA class I loss in cancer immunotherapy: facts and hopes","volume":"28","author":"Aptsiauri","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.iotech.2026.101611_bib85","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/01.ju.0000094807.95420.fe","article-title":"Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma?","volume":"171","author":"Atkins","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.iotech.2026.101611_bib86","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.juro.2006.11.082","article-title":"Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma","volume":"177","author":"Kitamura","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.iotech.2026.101611_bib87","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.acthis.2012.11.002","article-title":"Down-regulation of human leukocyte antigen class I (HLA-I) is associated with poor prognosis in patients with clear cell renal cell carcinoma","volume":"115","author":"Yuan","year":"2013","journal-title":"Acta Histochem"},{"key":"10.1016\/j.iotech.2026.101611_bib88","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO-25-00234","article-title":"Tumor-intrinsic and microenvironmental determinants of impaired antitumor immunity in chromophobe renal cell carcinoma","volume":"43","author":"Labaki","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.iotech.2026.101611_bib89","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ccell.2024.03.002","article-title":"Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes","volume":"42","author":"Saliby","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.iotech.2026.101611_bib90","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ccell.2021.02.013","article-title":"Progressive immune dysfunction with advancing disease stage in renal cell carcinoma","volume":"39","author":"Braun","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.iotech.2026.101611_bib91","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006885","article-title":"Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma","volume":"11","author":"De Vries-Brilland","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.iotech.2026.101611_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1182581","article-title":"Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles","volume":"14","author":"Govindarajan","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.iotech.2026.101611_bib93","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: from mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.iotech.2026.101611_bib94","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.cell.2017.04.016","article-title":"An immune atlas of clear cell renal cell carcinoma","volume":"169","author":"Chevrier","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.iotech.2026.101611_bib95","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ccell.2021.02.015","article-title":"Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma","volume":"39","author":"Bi","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.iotech.2026.101611_bib96","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41419-022-04501-9","article-title":"Heterogeneity of tumor microenvironment is associated with clinical prognosis of non-clear cell renal cell carcinoma: a single-cell genomics study","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.iotech.2026.101611_bib97","doi-asserted-by":"crossref","unstructured":"Bennion KB, Liang W, Zhang Y, et al. Macrophage-derived Fgl2 dampens antitumor immunity through regulation of Fc\u03b3RIIB+CD8+ T cells in melanoma. JCI Insight. 10:e182563.","DOI":"10.1172\/jci.insight.182563"},{"key":"10.1016\/j.iotech.2026.101611_bib98","first-page":"S21","article-title":"Spatial clustering of immunosuppressive macrophages in papillary renal cell carcinoma","volume":"29","author":"Hayes","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.iotech.2026.101611_bib99","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/path.70001","article-title":"Papillary renal cell carcinoma with high-ABCC2 shows an immune-evasive profile associated with favorable response to immunotherapy","volume":"268","author":"Castillo","year":"2025","journal-title":"J Pathol"},{"key":"10.1016\/j.iotech.2026.101611_bib100","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.iotech.2026.101611_bib101","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41423-020-00577-5","article-title":"The cutting-edge progress of immune-checkpoint blockade in lung cancer","volume":"18","author":"Zhou","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.iotech.2026.101611_bib102","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009495","article-title":"Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214","volume":"12","author":"Mantia","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.iotech.2026.101611_bib103","series-title":"Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study","author":"Motzer","year":"2026"},{"key":"10.1016\/j.iotech.2026.101611_bib104","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-58436-8","article-title":"Angiogenic and immune predictors of neoadjuvant axitinib response in renal cell carcinoma with venous tumour thrombus","volume":"16","author":"Wray","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.iotech.2026.101611_bib105","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1470-2045(23)00276-0","article-title":"Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial","volume":"24","author":"Albiges","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.iotech.2026.101611_bib106","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.annonc.2025.03.016","article-title":"Prospective randomized phase-II trial of ipilimumab\/nivolumab versus standard of care in non-clear cell renal cell cancer\u2014results of the SUNNIFORECAST trial","volume":"36","author":"Bergmann","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.iotech.2026.101611_bib107","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1158\/1541-7786.MCR-25-0939","article-title":"Non-clear cell renal cell carcinoma has an immune-cold phenotype that affects response to immune checkpoint inhibitors","volume":"24","author":"Ishihara","year":"2026","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.iotech.2026.101611_bib108","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.eururo.2021.03.015","article-title":"A single-arm, multicenter, phase 2 study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma","volume":"80","author":"Hutson","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.iotech.2026.101611_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104985","article-title":"Chromophobe renal cell carcinoma: emerging vulnerabilities as a promise for a new therapeutic landscape","volume":"216","author":"Salem","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.iotech.2026.101611_bib110","doi-asserted-by":"crossref","first-page":"E6272","DOI":"10.1073\/pnas.1710849115","article-title":"Impairment of gamma-glutamyl transferase 1 activity in the metabolic pathogenesis of chromophobe renal cell carcinoma","volume":"115","author":"Priolo","year":"2018","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.iotech.2026.101611_bib111","article-title":"Hypersensitivity to ferroptosis in chromophobe RCC is mediated by a glutathione metabolic dependency and cystine import via solute carrier family 7 member 11","volume":"119","author":"Zhang","year":"2022","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.iotech.2026.101611_bib112","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1038\/s41388-025-03562-2","article-title":"Targeting FSP1 to induce ferroptosis in chromophobe renal cell carcinoma","volume":"44","author":"Salem","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.iotech.2026.101611_bib113","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.1158\/0008-5472.CAN-21-1547","article-title":"A dual PI3K\/HDAC inhibitor induces immunogenic ferroptosis to potentiate cancer immune checkpoint therapy","volume":"81","author":"Fan","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.iotech.2026.101611_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102463","article-title":"Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing","volume":"56","author":"Hao","year":"2022","journal-title":"Redox Biol"},{"key":"10.1016\/j.iotech.2026.101611_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2025.103796","article-title":"Ferroptosis triggers anti-tumor immunity via promoting chaperone-mediated autophagic degradation of SHP2","volume":"86","author":"Zhu","year":"2025","journal-title":"Redox Biol"}],"container-title":["Immuno-Oncology and Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018826000304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018826000304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:01:28Z","timestamp":1790265688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590018826000304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":115,"alternative-id":["S2590018826000304"],"URL":"https:\/\/doi.org\/10.1016\/j.iotech.2026.101611","relation":{},"ISSN":["2590-0188"],"issn-type":[{"value":"2590-0188","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reviving cancer vaccines in renal cell carcinoma: a new chapter in immunotherapy for kidney cancer","name":"articletitle","label":"Article Title"},{"value":"Immuno-Oncology and Technology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iotech.2026.101611","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101611"}}